New diabetes drug shows safety over one year in japanese patients
NCT ID NCT01301833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety of MP-513 (Teneligliptin) in 462 Japanese adults with type 2 diabetes. Participants took the drug alone or with other oral diabetes medicines for 52 weeks. The main goal was to track side effects, and researchers also measured blood sugar control. The study is complete and provides safety data for this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Chitose-shi, Hokkaido, Japan